Luis Rodriguez

Research Assistant

Luis Rodriguez

Research Assistant

Current Employment

Regeneron Pharmaceuticals, Tarrytown, NY.

Publications

Manuscripts 

  • Servais EL, Colovos C, Rodriguez L, Bograd AJ, Nitadori J, Sima C, Rusch VW, Sadelain M, Adusumilli PS. Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients. Clin Cancer Res. 2012 May 1;18(9):2478-89. PMID: 22371455; PMCID: PMC3759995.
  • Servais EL, Suzuki K, Colovos C, Rodriguez L, Sima C, Fleisher M, Rusch VW, Sadelain M, Adusumilli PS. An In Vivo Platform for Tumor Biomarker Assessment. PLoS ONE. 2011; 6(10): e26722. PMID 22046338.
  • Servais EL, Colovos C, Suzuki K, Velez M, Rodriguez L, Sima C, Rusch VW, Sadelain M, Adusumilli PS. Mesothelin is a biomarker of tumor aggressiveness and therapy response in malignant pleural mesothelioma (MPM). J Am Coll Surg. 2010; 211(3): S36.

Abstracts/Presentations

  • Villena-Vargas J, Rodriguez L, Moroz M, Cherkassky L, Rusch VW, Sadelain M, Ponomarev V, Adusumilli PS. T-cell imaging to noninvasively monitor adoptive T-cell therapy for thoracic malignancies. International Association for the Study of Lung Cancer (IASLC) 15th World Conference on Lung Cancer, October 27-30, 2013, Sydney, Australia.
  • Villena-Vargas J, Cherkassky L, Colovos C, Servais E, Rodriguez L, Rusch VW, Sadelain M, Adusumilli PS. Critical role of CD28 costimulation in tumor-targeted T-cell therapy clinical trial for pleural malignancies. International Association for the Study of Lung Cancer (IASLC) 15th World Conference on Lung Cancer, October 27-30, 2013, Sydney, Australia.
  • Bograd A, Villena-Vargas J, Kachala S, Servais E, Colovos C, Rodriguez L, Rusch VW, Sadelain M, Adusumilli PS. Mesothelin-targeted T-cell therapy optimized for the lung adenocarcinoma tumor microenvironment. International Association for the Study of Lung Cancer (IASLC) 15th World Conference on Lung Cancer, October 27-30, 2013, Sydney, Australia.
  • Kachala S, Bograd AJ, Rodriguez L, Servais EL, Kadota K, Sima C, Rusch VW, Travis WD, Sadelain M, Adusumilli PS. Mesothelin decreases recurrence-free survival in lung adenocarcinoma by imparting an aggressive phenotype. American Association for Thoracic Surgery meeting. May 4-8, 2013; Minneapolis. MN (Oral Presentation).
  • Servais EL, Colovos C, Rodriguez L, Bograd AJ, Nitadori J, Sima C, Sadelain M, Rusch VW, Adusumilli PS. Mesothelin promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in malignant pleural mesothelioma (MPM) patients: a potential mechanism for MPM regional aggressiveness. American Association for Thoracic Surgery 2012, Lillehei Forum, May 2012, San Francisco, CA.
  • Kachala SS, Suzuki K, Vertes E, Rodriguez L, Kadota K, Sima CS, Rusch VW, Travis WD, Sadelain M, Adusumilli PS. Mesothelin is a commonly expressed tumor marker in lung adenocarcinoma (LAC) that imparts an aggressive phenotype—a candidate molecular target. International Association for the Study of Lung Cancer (IASLC) 14th World Conference on Lung Cancer, July 2-5, 2011, Amsterdam, the Netherlands.
  • Colovos C, Bograd AJ, Cavnar MJ, Rodriguez L, Rusch VW, Sadelain M, Adusumilli PS. An Immunocompetent orthotopic mouse model of malignant pleural mesothelioma permits pleural tumor immune microenvironment characterization and intrapleural interleukin-12 therapy. International Association for the Study of Lung Cancer (IASLC) 14th World Conference on Lung Cancer, July 2-5, 2011, Amsterdam, The Netherlands.
  • Servais EL, Suzuki K, Fleisher M, Sima C, Colovos C, Rodriguez L, Rusch VW, Sadelain M, Adusumilli PS. An in vivo platform for biomarker validation in malignant pleural mesothelioma. 10th International Conference of the International Mesothelioma Interest Group (IMIG), August 31-September 3, 2010, Kyoto, Japan.
  • Servais EL, Colovos C, Kachala SS, Rodriguez L, Kadota K, Rusch VW, Sadelain M, Adusumilli PS. Mesothelin expression promotes invasive phenotype and matrix metalloproteinase secretion in pleural mesothelioma. 10th International Conference of the International Mesothelioma Interest Group (IMIG), August 31-September 3, 2010, Kyoto, Japan.
  • Servais EL, Colovos C, Rodriguez L, Velez MC, Rusch VW, Sadelain M, Adusumilli PS. Location matters: biological significance of pleural microenvironment in mesothelioma murine models. 10th International Conference of the International Mesothelioma Interest Group (IMIG), August 31-September 3, 2010, Kyoto, Japan.
  • Servais EL, Colovos C, Suzuki K, Velez M, Rodriguez L, Sima C, Rusch VW, Sadelain M, Adusumilli PS. Mesothelin is a biomarker of tumor aggressiveness and therapy response in malignant pleural mesothelioma (MPM). Oral presentation in surgical forum: American College of Surgeons 96th Annual Clinical Congress, October 3-7, 2010, Washington, DC.
  • Colovos C, Servais EL, Kachala SK, Rodriguez L, Kadota K, Rusch VW, Sadelain M, Adusumilli PS. Significance of tumor microenvironment in preclinical investigation of malignant pleural mesothelioma. International Symposium on Malignant Mesothelioma, June 10-12, 2010, Washington, DC.
  • Rodriguez L, Colovos C, Servais EL, Rusch VW, Sadelain M, Adusumilli PS. WT-1 targeted immunotherapy for malignant pleural mesothelioma. International Symposium on Malignant Mesothelioma, June 10-12, 2010, Washington, DC.
  • Servais EL, Colovos C, Suzuki K, Rodriguez L, Sima C, Rusch VW, Sadelain M, Adusumilli PS. Biomarker validation for a rare malignancy in a mouse model. AACR 100th Annual Meeting, April 17-20, 2010, Washington, DC.